|
1
|
Sytkowski AJ: Erythropoietin: Blood, Brain
and Beyond. Wiley-VCH; Weinheim: 2004, View Article : Google Scholar
|
|
2
|
Miller CP, Lowe KA, Valliant-Saunders K,
et al: Evaluating erythropoietin-associated tumor progression using
archival tissues from a phase III clinical trial. Stem Cells.
27:2353–2361. 2009. View
Article : Google Scholar
|
|
3
|
Swift S, Ellison AR, Kassner P, et al:
Absence of functional EpoR expression in human tumor cell lines.
Blood. 115:4254–4263. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jeong JY, Feldman L, Solar P, Szenajch J
and Sytkowski AJ: Characterization of erythropoietin receptor and
erythropoietin expression and function in human ovarian cancer
cells. Int J Cancer. 122:274–280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu
X and Acs G: RNA interference-mediated inhibition of erythropoietin
receptor expression suppresses tumor growth and invasiveness in
A2780 human ovarian carcinoma cells. Am J Pathol. 174:1504–1514.
2009. View Article : Google Scholar
|
|
6
|
Solar P, Hrckova G, Varinska L, et al:
Location and the functionality of erythropoietin receptor(s) in
A2780 cells. Oncol Rep. 28:141–146. 2012.PubMed/NCBI
|
|
7
|
Szenajch J, Wcislo G, Jeong JY, Szczylik C
and Feldman L: The role of erythropoietin and its receptor in
growth, survival and therapeutic response of human tumor cells From
clinic to bench - a critical review. Biochim Biophys Acta.
1806:82–95. 2010.PubMed/NCBI
|
|
8
|
Anagnostou A, Lee ES, Kessimian N,
Levinson R and Steiner M: Erythropoietin has a mitogenic and
positive chemotactic effect on endothelial cells. Proc Natl Acad
Sci USA. 87:5978–5982. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carlini RG, Dusso AS, Obialo CI, Alvarez
UM and Rothstein M: Recombinant human erythropoietin (rHuEPO)
increases endothelin-1 release by endothelial cells. Kidney Int.
43:1010–1014. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carlini RG, Reyes AA and Rothstein M:
Recombinant human erythropoietin stimulates angiogenesis in vitro.
Kidney Int. 47:740–745. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Anagnostou A, Liu Z, Steiner M, et al:
Erythropoietin receptor mRNA expression in human endothelial cells.
Proc Natl Acad Sci USA. 91:3974–3978. 1994.PubMed/NCBI
|
|
12
|
Yamaji R, Okada T, Moriya M, et al: Brain
capillary endothelial cells express two forms of erythropoietin
receptor mRNA. Eur J Biochem. 239:494–500. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yasuda Y, Masuda S, Chikuma M, Inoue K,
Nagao M and Sasaki R: Estrogen-dependent production of
erythropoietin in uterus and its implication in uterine
angiogenesis. J Biol Chem. 273:25381–25387. 1998.PubMed/NCBI
|
|
14
|
Ribatti D, Presta M, Vacca A, et al: Human
erythropoietin induces a pro-angiogenic phenotype in cultured
endothelial cells and stimulates neovascularization in vivo. Blood.
93:2627–2636. 1999.PubMed/NCBI
|
|
15
|
Haroon ZA, Amin K, Jiang X and Arcasoy MO:
A novel role for erythropoietin during fibrin-induced wound-healing
response. Am J Pathol. 163:993–1000. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kertesz N, Wu J, Chen TH, Sucov HM and Wu
H: The role of erythropoietin in regulating angiogenesis. Dev Biol.
276:101–110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yasuda Y, Fujita Y, Musha T, et al:
Expression of erythropoietin in human female reproductive organs.
Ital J Anat Embryol. 106(Suppl 2): S215–S222. 2001.PubMed/NCBI
|
|
18
|
Yasuda Y, Fujita Y, Masuda S, et al:
Erythropoietin is involved in growth and angiogenesis in malignant
tumours of female reproductive organs. Carcinogenesis.
23:1797–1805. 2002. View Article : Google Scholar
|
|
19
|
Nakamatsu K, Nishimura Y, Suzuki M,
Kanamori S, Maenishi O and Yasuda Y:
Erythropoietin/erythropoietin-receptor system as an angiogenic
factor in chemically induced murine hepatic tumors. Int J Clin
Oncol. 9:184–188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nico B, Annese T, Guidolin D, Finato N,
Crivellato E and Ribatti D: Epo is involved in angiogenesis in
human glioma. J Neurooncol. 102:51–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kumar SM, Zhang G, Bastian BC, et al:
Erythropoietin receptor contributes to melanoma cell survival in
vivo. Oncogene. 31:1649–1660. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okazaki T, Ebihara S, Asada M, Yamanda S,
Niu K and Arai H: Erythropoietin promotes the growth of tumors
lacking its receptor and decreases survival of tumor-bearing mice
by enhancing angiogenesis. Neoplasia. 10:932–939. 2008.PubMed/NCBI
|
|
23
|
Ribatti D, Marzullo A, Gentile A, et al:
Erythropoietin/erythropoietin-receptor system is involved in
angiogenesis in human hepatocellular carcinoma. Histopathology.
50:591–596. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ribatti D, Nico B, Perra MT, et al:
Erythropoietin is involved in angiogenesis in human primary
melanoma. Int J Exp Pathol. 91:495–499. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li HG, Li JS, Chen WL, Wang L, Wu DH and
Lin ZY: Prognostic significance of erythropoietin and
erythropoietin receptor in tongue squamous cell carcinoma. Br J
Oral Maxillofac Surg. 47:470–475. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ribatti D: Erythropoietin and tumor
angiogenesis. Stem Cells Dev. 19:1–4. 2010. View Article : Google Scholar
|
|
27
|
Wang L, Li HG, Xia ZS, Wen JM and Lv J:
Prognostic significance of erythropoietin and erythropoietin
receptor in gastric adenocarcinoma. World J Gastroenterol.
17:3933–3940. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Van Hinsbergh VW, Sprengers ED and
Kooistra T: Effect of thrombin on the production of plasminogen
activators and PA inhibitor-1 by human foreskin microvascular
endothelial cells. Thromb Haemost. 57:148–153. 1987.PubMed/NCBI
|
|
29
|
Defilippi P, van Hinsbergh V, Bertolotto
A, Rossino P, Silengo L and Tarone G: Differential distribution and
modulation of expression of alpha 1/beta 1 integrin on human
endothelial cells. J Cell Biol. 114:855–863. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arcasoy MO, Jiang X and Haroon ZA:
Expression of erythropoietin receptor splice variants in human
cancer. Biochem Biophys Res Commun. 307:999–1007. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Westenfelder C and Baranowski RL:
Erythropoietin stimulates proliferation of human renal carcinoma
cells. Kidney Int. 58:647–657. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lai SY, Childs EE, Xi S, et al:
Erythropoietin-mediated activation of JAK-STAT signaling
contributes to cellular invasion in head and neck squamous cell
carcinoma. Oncogene. 24:4442–4449. 2005. View Article : Google Scholar
|
|
33
|
Feldman L, Wang Y, Rhim JS, Bhattacharya
N, Loda M and Sytkowski AJ: Erythropoietin stimulates growth and
STAT5 phosphorylation in human prostate epithelial and prostate
cancer cells. Prostate. 66:135–145. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Selzer E, Wacheck V, Kodym R, et al:
Erythropoietin receptor expression in human melanoma cells.
Melanoma Res. 10:421–426. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Solar P, Koval J, Mikes J, et al:
Erythropoietin inhibits apoptosis induced by photodynamic therapy
in ovarian cancer cells. Mol Cancer Ther. 7:2263–2271. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Karar J and Maity A: PI3K/AKT/mTOR pathway
in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Solar P, Feldman L, Jeong JY, Busingye JR
and Sytkowski AJ: Erythropoietin treatment of human ovarian cancer
cells results in enhanced signaling and a paclitaxel-resistant
phenotype. Int J Cancer. 122:281–288. 2008. View Article : Google Scholar
|
|
39
|
Hale SA, Wong C and Lounsbury KM:
Erythropoietin disrupts hypoxia-inducible factor signaling in
ovarian cancer cells. Gynecol Oncol. 100:14–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Haller H, Christel C, Dannenberg L, Thiele
P, Lindschau C and Luft FC: Signal transduction of erythropoietin
in endothelial cells. Kidney Int. 50:481–488. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Janmaat ML, Heerkens JL, de Bruin AM,
Klous A, de Waard V and de Vries CJ: Erythropoietin accelerates
smooth muscle cell-rich vascular lesion formation in mice through
endothelial cell activation involving enhanced PDGF-BB release.
Blood. 115:1453–1460. 2010. View Article : Google Scholar
|
|
42
|
Sonoda T, Kobayashi H, Kaku T, Hirakawa T
and Nakano H: Expression of angiogenesis factors in monolayer
culture, multicellular spheroid and in vivo transplanted tumor by
human ovarian cancer cell lines. Cancer Lett. 196:229–237. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lidor YJ, Xu FJ, Martinez-Maza O, et al:
Constitutive production of macrophage colony-stimulating factor and
interleukin-6 by human ovarian surface epithelial cells. Exp Cell
Res. 207:332–339. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Di Blasio AM, Carniti C, Vigano P and
Vignali M: Basic fibroblast growth factor and ovarian cancer. J
Steroid Biochem Mol Biol. 53:375–379. 1995.PubMed/NCBI
|
|
45
|
Versnel MA, Haarbrink M, Langerak AW, et
al: Human ovarian tumors of epithelial origin express PDGF in vitro
and in vivo. Cancer Genet Cytogenet. 73:60–64. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Negus RP, Stamp GW, Relf MG, et al: The
detection and localization of monocyte chemoattractant protein-1
(MCP-1) in human ovarian cancer. J Clin Invest. 95:2391–2396. 1995.
View Article : Google Scholar
|
|
47
|
Savarese TM, Mitchell K, McQuain C, et al:
Coexpression of granulocyte colony stimulating factor and its
receptor in primary ovarian carcinomas. Cancer Lett. 162:105–115.
2001.PubMed/NCBI
|
|
48
|
Glezerman M, Mazot M, Maymon E, et al:
Tumor necrosis factor-alpha and interleukin-6 are differently
expressed by fresh human cancerous ovarian tissue and primary cell
lines. Eur Cytokine Netw. 9:171–179. 1998.PubMed/NCBI
|
|
49
|
Gorelik E, Landsittel DP, Marrangoni AM,
et al: Multiplexed immunobead-based cytokine profiling for early
detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev.
14:981–987. 2005. View Article : Google Scholar
|
|
50
|
Muller L and Pawelec G: Cytokines and
antitumor immunity. Technol Cancer Res Treat. 2:183–194. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Coward J, Kulbe H, Chakravarty P, et al:
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin
Cancer Res. 17:6083–6096. 2011. View Article : Google Scholar
|
|
52
|
Kohno T, Mizukami H, Suzuki M, et al:
Interleukin-10-mediated inhibition of angiogenesis and tumor growth
in mice bearing VEGF-producing ovarian cancer. Cancer Res.
63:5091–5094. 2003.PubMed/NCBI
|
|
53
|
Volpert OV, Fong T, Koch AE, et al:
Inhibition of angiogenesis by interleukin 4. J Exp Med.
188:1039–1046. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Akhtar N, Padilla ML, Dickerson EB, et al:
Interleukin-12 inhibits tumor growth in a novel angiogenesis canine
hemangiosarcoma xenograft model. Neoplasia. 6:106–116. 2004.
View Article : Google Scholar : PubMed/NCBI
|
